CliffBio
biologic

Opdualag

nivolumab and relatlimab-rmbw

Loss of exclusivityMarch 2034projected — 12-year biologic exclusivity estimate
CompanyBristol-Myers Squibb Company →View the full company profile on CliffBio

Drug detail

Brand nameOpdualag
Active ingredientnivolumab and relatlimab-rmbw
Strength240MG, 80MG/20ML (12MG, 4MG/ML)
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalMarch 2022
Marketing statusRx

More from Bristol-Myers Squibb Company

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Opdualag patent cliff — loss of exclusivity March 2034 | CliffBio